Kyowa Kirin enrols first subject in Phase II diabetic macular edema trial

Japan’s Kyowa Kirin has commenced a Phase II clinical trial of tivozanib eye drops (KHK4951) for diabetic macular oedema (DME), with the first subject now enrolled.

The trial aims to assess the safety and efficacy of KHK4951 in patients with DME across multiple countries, including the US, Japan, Australia, and South Korea.